Conference Details - Agenda

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Fifth Annual New York Lung Cancer Symposium

The Westin New York at Times Square
New York, NY
November 10, 2009

Tuesday, November 10, 2009

7:30 am Registration and Continental Breakfast
8:00 am Welcome and Introductions
Vincent Miller, Román Pérez-Soler
8:05 am Presession Survey
What Oncologists Need to Know About Lung Cancer Pathology
8:15 am New Technologies to Diagnose Lung Cancer Subtypes
8:35 am Algorithmic Approaches for Small Biopsy Specimens: Getting More Information From Less Tissue
William D. Travis
8:55 am Molecular Subtyping of Lung Cancer
Marc Ladanyi
9:15 am Panel Discussion/Question-and-Answer Session
Maintenance Therapy in Advanced NSCLC
9:30 am Chemotherapy
Nasser H. Hanna
9:50 am Targeted Agents
Vincent Miller
  Debate: Maintenance Therapy Should Be the Standard of Care
10:10 am PRO
Richard Gralla
10:25 am CON
Heather Wakelee
10:40 am Panel Discussion/Question-and-Answer Session
10:35 am Break
Approaches to Early NSCLC and Chemoprevention
10:50 am Current Approaches to Adjuvant Therapy in Resectable NSCLC
Steven M. Keller
11:10 am Nonsurgical Interventions for Early Lung Cancer
Stephen Solomon
11:30 am Chemoprevention in Lung Cancer
Fadlo R. Khuri
11:50 am Postsession Survey
12:00 pm Panel Discussion/Question-and-Answer Session
12:15 pm Break to Serve Lunch
12:25 pm Fellows Case Discussion Session and Working Lunch
Abraham Chachoua, Harry Raftopoulos
1:25 pm Presession Survey
Novel Agents and Applications for Lung Cancer
1:35 pm Overview
Alex Adjei
1:55 pm Angiogenesis Inhibitors: What’s New?
Román Pérez-Soler
2:10 pm EML4-ALK–Positive Lung Cancer: Therapeutic Approaches for an Emerging Subtype
Lecia V. Sequist
2:25 pm Update on the Role of IGF-1R Inhibitors
Mark G. Kris
2:40 pm What’s New With EGFR Inhibitors: Biomarkers and Frontline TKI Use
3:10 pm Update on Adverse Events With Novel Agents/Chemotherapy
Román Pérez-Soler
3:30 pm Postsession Survey
3:40 pm Panel Discussion/Question-and-Answer Session
4:00 pm Adjourn

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology/
    OSI Oncology
  2. Eli Lilly and Company
  3. Boehringer Ingelheim Pharmaceuticals, Inc.
  4. Agennix, Inc.